ethyl 2-(4,6-dihydroxypyrimidin-2-ylthio)-2-phenylacetate | 461431-94-7

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: ethyl 2-(4,6-dihydroxypyrimidin-2-ylthio)-2-phenylacetate
• 英文别名: ethyl 2-[(4-hydroxy-6-oxo-1H-pyrimidin-2-yl)sulfanyl]-2-phenylacetate
• CAS: 461431-94-7
• 化学式: C₁₄H₁₄N₂O₄S
• 分子量: 306.342
• InChiKey: WADHYYFQEIUSHL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  113
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  ethyl 2-(4,6-dihydroxypyrimidin-2-ylthio)-2-phenylacetate 在 三氯氧磷 作用下， 生成
  参考文献：
  名称：

  α-烷基取代的哌立尼克酸衍生物作为过氧化物酶体增殖物激活受体α和γ的强效双重激动剂

  摘要：

  过氧化物酶体增殖物激活受体 (PPAR) 是核受体，在能量稳态中起关键作用。PPARα 亚型激活剂广泛用于治疗高脂血症，而 PPARγ 亚型激活剂在临床上用于治疗 2 型糖尿病。由于这两种疾病经常相互关联，因此用一种同时激活 PPARα 和 PPARγ 的药物进行联合治疗似乎是值得的。从吡立昔酸开始，它是一种中等活性的双 PPARα/γ 激动剂，我们通过用脂肪链取代 α- 位来提高对人 PPARα 和 PPARγ 的效力。分别在四个碳和六个碳的链长处达到最大效果，导致 PPARα 的活性诱导因子分别为 36 和 PPARγ 的因子为 18。

  DOI：

  10.1002/ardp.200700209
• 作为产物：
  描述：

  2-Thiobarbituric acid 、 α-溴苯乙酸乙酯 在 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以85.1%的产率得到ethyl 2-(4,6-dihydroxypyrimidin-2-ylthio)-2-phenylacetate
  参考文献：
  名称：

  Design, Synthesis, and Biological Evaluation of a Novel Class of γ-Secretase Modulators with PPARγ Activity

  摘要：

  We present a novel class of dual modulators of gamma-secretase and peroxisome proliferator-activated receptor gamma (PPAR gamma) based on the structure of 2-(bis(phenethoxy)pyrimidine-2-ylthio)hexanoic acid 8 (IC50(A beta 42) = 22.8 mu M, EC50(PPAR gamma) = 8.3 mu M). The modulation of both targets with approved drugs (i.e., amyloid-beta 42 (A beta 42)-lowering NSAIDs for gamma-secretase and glitazones for PPAR gamma) has demonstrated beneficial effects in in vitro and in vivo models of Alzheimer's disease (AD). However, although NSAIDs and PPAR gamma agonists share similar structural features, no druglike compounds with dual activities as gamma-secretase modulators (GSMs) and PPAR gamma agonists have been designed so far. On the basis of our initial lead structure 8, we present the structure-activity relationships (SARs) of broad structural variations. A significant improvement was reached by the introduction of p-trifluoromethyl substituents at the phenyl residues yielding compound 16 (IC50(A beta 42) = 6.0 mu M, EC50(PPAR gamma) = 11.0 mu M) and the replacement of the two phenyl residues of 8 by cyclohexyl yielding compound 22 (IC50(A beta 42) = 5.1 mu M, EC50(PPAR gamma) = 6.6 mu M).

  DOI：

  10.1021/jm1003073

文献信息

• Design, Synthesis, and Biological Evaluation of a Novel Class of γ-Secretase Modulators with PPARγ Activity
  作者：Martina Hieke、Julia Ness、Ramona Steri、Michaela Dittrich、Christine Greiner、Oliver Werz、Karlheinz Baumann、Manfred Schubert-Zsilavecz、Sascha Weggen、Heiko Zettl

  DOI：10.1021/jm1003073

  日期：2010.6.24

  We present a novel class of dual modulators of gamma-secretase and peroxisome proliferator-activated receptor gamma (PPAR gamma) based on the structure of 2-(bis(phenethoxy)pyrimidine-2-ylthio)hexanoic acid 8 (IC50(A beta 42) = 22.8 mu M, EC50(PPAR gamma) = 8.3 mu M). The modulation of both targets with approved drugs (i.e., amyloid-beta 42 (A beta 42)-lowering NSAIDs for gamma-secretase and glitazones for PPAR gamma) has demonstrated beneficial effects in in vitro and in vivo models of Alzheimer's disease (AD). However, although NSAIDs and PPAR gamma agonists share similar structural features, no druglike compounds with dual activities as gamma-secretase modulators (GSMs) and PPAR gamma agonists have been designed so far. On the basis of our initial lead structure 8, we present the structure-activity relationships (SARs) of broad structural variations. A significant improvement was reached by the introduction of p-trifluoromethyl substituents at the phenyl residues yielding compound 16 (IC50(A beta 42) = 6.0 mu M, EC50(PPAR gamma) = 11.0 mu M) and the replacement of the two phenyl residues of 8 by cyclohexyl yielding compound 22 (IC50(A beta 42) = 5.1 mu M, EC50(PPAR gamma) = 6.6 mu M).
• α-Alkyl Substituted Pirinixic Acid Derivatives as Potent Dual Agonists of the Peroxisome Proliferator Activated Receptor Alpha and Gamma
  作者：Oliver Rau、Yvonne Syha、Heiko Zettl、Michael Kock、Andreas Bock、Manfred Schubert-Zsilavecz

  DOI：10.1002/ardp.200700209

  日期：2008.3

  Peroxisome proliferator‐activated receptors (PPAR) are nuclear receptors, playing a pivotal role in energy homeostasis. Activators of the PPARα subtype are in widespread use for the treatment of hyperlipidemia, while activators of the PPARγ subtype are in clinical use for the treatment of type‐2 diabetes. Since both of these diseases are frequently associated, the combined treatment with one drug simultaneously

  过氧化物酶体增殖物激活受体 (PPAR) 是核受体，在能量稳态中起关键作用。PPARα 亚型激活剂广泛用于治疗高脂血症，而 PPARγ 亚型激活剂在临床上用于治疗 2 型糖尿病。由于这两种疾病经常相互关联，因此用一种同时激活 PPARα 和 PPARγ 的药物进行联合治疗似乎是值得的。从吡立昔酸开始，它是一种中等活性的双 PPARα/γ 激动剂，我们通过用脂肪链取代 α- 位来提高对人 PPARα 和 PPARγ 的效力。分别在四个碳和六个碳的链长处达到最大效果，导致 PPARα 的活性诱导因子分别为 36 和 PPARγ 的因子为 18。